Concepedia

Sarina A. Piha‐Paul

SA

266

Publications

29.7K

Citations

71

H-Index

1997

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Dana-Farber Cancer Institute

Merck & Co., Inc., Rahway, NJ, USA (United States)

University of California San Diego

Institut Gustave Roussy

Sarina A. Piha‐Paul is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and radiation oncology.

ORCID

Top concepts

Publications per year

1997–2025

266

Publications

266

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Mark Ayers, Jared Lunceford, Michael Nebozhyn et al. · Journal of Clinical Investigation · 2017 · 3.7K citations · Full text

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto et al. · Journal of Clinical Oncology · 2019 · 2.8K citations · Full text

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle, Marwan Fakih, Juanita Lopez et al. · The Lancet Oncology · 2020 · 2.4K citations · Full text

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

Hyun Cheol Chung, Willeke Ros, Jean‐Pierre Delord et al. · Journal of Clinical Oncology · 2019 · 1K citations · Full text

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Patrick A. Ott, Yung‐Jue Bang, Sarina A. Piha‐Paul et al. · Journal of Clinical Oncology · 2018 · 965 citations

Rows per page

1–5 of 266